Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism
Current strategies for the treatment of hereditary angioedema (HAE) include targeted inhibition or antagonism of the contact system, which is dysregulated in HAE patients by a C1 esterase inhibitor deficiency. Ecallantide, a plasma kallikrein inhibitor, and icatibant, a selective bradykinin-2 recept...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010-01-01
|
| Series: | World Allergy Organization Journal |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455119304983 |